Bloomberg
Best Practices in Light of Growing Accumulator Program Activities
June 5, 2024
In recent years, there has been an increased prevalence in the marketplace of so-called accumulator programs, which exclude the value of pharmaceutical cost-sharing assistance (e.g., coupons, drug discount cards, copay assistance programs) from patients’ annual cost-sharing responsibilities to their insurers. The existence of these copay accumulator programs is often unknown to either the patient or the manufacturer sponsoring the cost-sharing assistance. Meena Datta, Ben Correa, and Kathy Lee discuss best practices for navigating these programs.
Contacts
Capabilities
Suggested News & Insights
U.S. Drug Pricing Year in Review: Reflections on 2025 and Getting Ready for 2026December 11, 2025CMS Announces Voluntary Most-Favored-Nation Pricing in Medicaid Through the GENEROUS ModelNovember 11, 2025Rare Disease and Specialty Product Manufacturers: Distribution Model ConsiderationsSeptember 16, 2025U.S. DOJ Announces Renewal of FCA Working GroupJuly 7, 2025CMS Sets Stage for 2028 Medicare Drug Price Negotiations — First Look at Negotiations for Part BMay 21, 2025Most-Favored-Nation Drug Pricing: Executive Order Sets Forth Potential U.S. Major Policy ShiftMay 15, 2025
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory


